1月6日，据CDE官网消息，石药集团巨石生物制药有限公司联合申请药品“SYS6045”，获得临床试验默示许可，受理号CXSL2400733。
公示信息显示，药品“SYS6045”适应症：实体瘤。
石药集团巨石生物制药有限公司，成立于2019年，位于石家庄市，是一家以从事医药制造业为主的企业。企业注册资本204081.6326万人民币，实缴资本100000万人民币。
通过天眼查大数据分析，石药集团巨石生物制药有限公司共对外投资了1家企业，参与招投标项目21次，专利信息32条，此外企业还拥有行政许可38个。
主要股东信息显示，石药集团巨石生物制药有限公司由石药创新制药股份有限公司持股51%、石药集团恩必普药业有限公司持股49%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.